MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12149-026-02287-w

Медицинская библиотека · Annals of nuclear medicine · 2026

Elevated baseline C-reactive protein is associated with treatment failure and shorter survival after Yttrium-90 radioembolization in hepatocellular carcinoma.

Kaya Enes Mustafa, Esen Akkaş Burcu, Güzelbey Tevfik, Erdim Çağrı, Arslan Mustafa Fatih, Şin Cihan, Kapucu Halil Burak, Dere Ayşe Betül, Kaya Meryem

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

To evaluate the impact of baseline C-reactive protein (CRP) on outcomes after yttrium-90 (Y-90) radioembolization (RE) for hepatocellular carcinoma (HCC).

METHODS

This retrospective study included patients with HCC treated with Y-90 RE at a tertiary center (June 2022-June 2025). Dosimetry was based on 99mTc-MAA SPECT/CT with refined post hoc high-dose definitions. High-dose therapy was defined as tumor-absorbed dose > 250 Gy for lobar treatments (glass or resin). For segmentectomy, high dose was defined as perfused-liver absorbed dose > 400 Gy for glass and > 250 Gy for resin microspheres. Patients were stratified by baseline CRP: low (≤ 1 mg/dL) vs. high (> 1 mg/dL). Tumor response was assessed on gadoxetate-enhanced MRI using mRECIST. Local progression-free survival (LPFS), progression-free survival (PFS), and overall survival (OS) were estimated by Kaplan-Meier and compared with log-rank tests. Cox regression identified independent prognostic factors.

RESULTS

The cohort comprised 103 patients (mean age 65.8 ± 9 years; 76.7% male). BCLC stages were A (n = 27), B (n = 35), and C (n = 41); median largest tumor diameter was 6.0 cm (IQR 4.1-8.8), and median follow-up was 26 months. On multivariable analysis, CRP > 1 mg/dL independently predicted inferior LPFS (HR 3.6, p < 0.001), PFS (HR 2.7, p = 0.002), and OS (HR 4.8, p < 0.001). High-dose treatment was independently associated with improved LPFS (HR 0.55, p = 0.043) and OS (HR 0.47, p = 0.021). In subgroup analyses, high-dose treatment was associated with longer survival in the low-CRP group but not in the high-CRP group.

CONCLUSION

Baseline CRP > 1 mg/dL is a strong adverse prognostic factor after Y-90 RE. High-dose RE was associated with longer survival in patients with low CRP but not in those with elevated CRP; this hypothesis-generating observation requires prospective confirmation.

Для цитирования: Kaya Enes Mustafa, Esen Akkaş Burcu, Güzelbey Tevfik, Erdim Çağrı, Arslan Mustafa Fatih, Şin Cihan, Kapucu Halil Burak, Dere Ayşe Betül, Kaya Meryem. Elevated baseline C-reactive protein is associated with treatment failure and shorter survival after Yttrium-90 radioembolization in hepatocellular carcinoma.. Annals of nuclear medicine. 2026. DOI: 10.1007/s12149-026-02287-w.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.